MET
MetLife
$87.56
▲ 2.3%Updated Today 7:15 PM ET
▲ Up 8.9% over the last 12 months
Market Cap
$55.07B
P/E
15.23x
Forward P/E (est.)
17.97x
ROE
12.9%
Revenue Growth
5.3%
EPS Growth
-15.2%
Profit Margin
4.7%
FCF Yield
—
Debt / Equity
0.67x
ROIC
10.0%
Interest Coverage
3.96x
Current Ratio
—
Dividend Yield
2.7%
Implied Growth (rev. DCF)
—
Rating Score
42/100
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what MET's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. MET trades near $87.56, above its 50-day average ($80.58) and 200-day average ($78.16). Price above both averages, with the shorter one above the longer, is the textbook definition of an uptrend — momentum favours buyers.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 63 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. MET's is $1.91 (~2.2% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month MET found buyers near $80.51 (support) and sellers near $89.62 (resistance); its 52-week range is $67.33–$89.62. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 1.5× the 20-day average — heavier than usual, which adds conviction to the move. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
MetLife (MET) is a large-cap company in the Life & Health Insurance industry, part of the Financials sector of the S&P 500, with a market value around $55.07B.
In its latest reported year it generated about $2.44B in revenue and $3.38B in net profit.
Our model rates MET Neutral (42/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
4Y CAGR
4.1%
Revenue moved from $2.07B in 2021 to $2.44B in 2025, a 4.1% compound annual growth rate. The most recent year grew a steady 5.3% year over year. Slower, mature growth is common for established businesses.
Gross Margin
—
Operating Margin
251.9%
Net Margin
138.7%
ROE
12.9%
MetLife keeps about 4.7% of each sales dollar as net profit. Return on equity is 12.9% and return on invested capital about 10.0%. Thin margins leave less cushion if costs rise.
Total Debt
$18.88B
Net Debt
-$3.81B
Net cash position
Net Debt / EBITDA
-0.62x
Debt / Equity
0.67x
Leverage: debt-to-equity is 0.7x, and operating profit covers interest about 4.0x. That is a moderate, manageable debt load for most businesses. It carries roughly $18.88B of total debt against $22.69B of cash.
Operating CF
$17.09B
Free Cash Flow
$17.09B
FCF Margin
701.6%
In the latest year MetLife produced about $17.09B of operating cash flow and $17.09B of free cash flow after capital spending. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
P/E
15.23x
P/S
0.73x
P/B
1.79x
EV / EBITDA
—
MET trades at 15.2x trailing earnings (about 18.0x on estimated forward earnings), 0.7x sales, and 1.8x book value. That is a fairly typical valuation for a profitable company.
Where this stock sits versus what most companies trade at.
Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.
How MET stacks up against its Financials peers — valuation, profitability, and growth versus the sector median.
In the Financials sector (76 S&P 500 companies), MET ranks #71 of 76 by our overall rating. It trades at roughly in line versus the sector on earnings (15.2x P/E vs. 15.2x median) with a lower return on equity (12.9% vs. 15.3%) and slower revenue growth (5.3% vs. 9.1%).
P/E vs sector
15.2x
median 15.2x
ROE vs sector
12.9%
median 15.3%
Growth vs sector
5.3%
median 9.1%
Sector rank
#71
of 76 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Financials companies by sub-industry and size. Sector median is across all 76 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$21.74 – $36.24
vs. $87.56 today · expected CAGR -24% – -16%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $2.56B | $2.69B | $2.82B | $2.96B | $3.11B |
| Net income | $1.28B | $1.34B | $1.41B | $1.48B | $1.55B |
| EPS | $1.99 | $2.09 | $2.19 | $2.30 | $2.42 |
| Share price (low) | $17.89 | $18.78 | $19.72 | $20.71 | $21.74 |
| Share price (high) | $29.81 | $31.30 | $32.87 | $34.51 | $36.24 |
| CAGR (low–high) | -80% / -66% | -54% / -40% | -39% / -28% | -30% / -21% | -24% / -16% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for MET:
- Pays a 2.7% dividend on top of any price gains.
- As an established S&P 500 member in Financials, it brings scale and a long operating history.
The case against MET:
- Thin net margins (4.7%) leave little room for error.
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Margin risk — thin profitability (4.7%) is vulnerable to cost or pricing pressure.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the picture is mixed: MetLife is a large-cap financials business growing at a mature pace, with modest profitability, and a sound balance sheet. It trades at 15.2x earnings, which our model scores Neutral (42/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.